Press Releases

FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label

Sets PDUFA goal date of January 24, 2024 If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD MORRISVILLE, N.C. , Sept. 25, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S.
Sep 25, 2023

U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation

Infringement case now only focused on ‘793 patent, previously found to be invalid by PTAB in IPR Federal Circuit expected to hear appeal of PTAB decision in late 4th quarter 2023 to early 2024 If PTAB decision affirmed, Liquidia will request final regulatory approval for YUTREPIA™ (treprostinil)
Jul 24, 2023

Liquidia Corporation to Present at the 2023 Jefferies Healthcare Conference

MORRISVILLE, N.C. , May 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that Mr. Roger Jeffs , Chief Executive Officer, and Mr. Michael Kaseta , Chief Financial Officer, will provide an update on the Company's business during a fireside chat at the
May 31, 2023
Displaying 21 - 30 of 177